ASCO News In Brief: IDEC Pharmaceuticals IDEC-C2B8
IDEC Pharmaceuticals IDEC-C2B8: Overall response rate of 47.9% reported in preliminary results of Phase III pivotal trial of single-agent antibody treatment for patients with relapsed low-grade or follicular non-Hodgkin's lymphoma. Fifty of 166 evaluable patients have been analyzed and full results should be available in December 1996, the company said. The tumor marker gene, bcl-2, reverted from positive to negative in the peripheral blood of 12 of 16 patients and in the bone marrow of six of 12 patients evaluated. IDEC is developing IDEC-C2B8 in collaboration with Genentech, Roche and Zenyaku Kogyo of Japan...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth